Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of sofosbuvir
(GS-7977; PSI-7977) administered in combination with pegylated interferon and ribavirin
(PEG/RBV) in treatment-naive patients with HCV genotypes 1,4,5,6, or indeterminate genotype.